Compound 968 reverses adriamycin resistance in breast cancer MCF-7(ADR) cells via inhibiting P-glycoprotein function independently of glutaminase

Adriamycin (ADR) is a chemotherapeutic drug widely utilized to treat multiple types of cancers; however, the clinical efficacy of ADR is compromised due to the development of drug resistance in patients. The combination of drugs with ADR may provide a better therapeutic regimen to overcome this obst...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ronghui, Guo, Zihao, Zhao, Yiliang, Ma, Lingdi, Li, Binghui, Yang, Chuanzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342604/
https://www.ncbi.nlm.nih.gov/pubmed/34354052
http://dx.doi.org/10.1038/s41420-021-00590-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342604/
https://www.ncbi.nlm.nih.gov/pubmed/34354052
http://dx.doi.org/10.1038/s41420-021-00590-1

Ejemplares similares